Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
August 10, 2016
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
- Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
August 8, 2016
- Astellas to Transfer US Manufacturing Unit to Avara
August 5, 2016
- Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
August 5, 2016
- Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
August 5, 2016
- Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
August 4, 2016
- Teijin Jettisons Extended-Release Version of Feburic; Successor Now in PI
August 3, 2016
- Mitsubishi Tanabe Erases Alzheimer’s Drug from Japan Pipeline
August 3, 2016
- Adcetris Shows Positive Efficacy Profile in Cutaneous T-Cell Lymphoma
August 3, 2016
- Takeda’s Cx601 Stem Cell Therapy Hits Primary Endpoint in Global PIII
August 3, 2016
- Shionogi to Transfer 21 Off-Patent Products to Kyowa Pharm
August 3, 2016
- Opdivo Hauls in 25.2 Billion Yen in April-June
August 3, 2016
- Nichi-Iko Launches Tender Offer for Sagent
August 3, 2016
- Japan Market Grows in April-June on Hep C Meds, Opdivo: IMS
August 2, 2016
- Gil Feldman Picked as President of Teva API Japan
August 2, 2016
- Halaven Extends Duration of Response in Soft Tissue Sarcoma: Global PIII
August 2, 2016
- Sunovion Submits US NDA for COPD Drug
August 2, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…